Physician profile
Christine M Haggerty
NPI 1457649089
$3,976.02
in general payments reported to CMS, 2019-2025
26 companies · $883 in 2025
The $883 reported for 2025 was more than what 83% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $536 · 2022: $158 · 2023: $1,378 · 2024: $1,022 · 2025: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,249 · Education: $34.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,248.83 |
| Education | $34.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,360.63 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $708.19 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $535.56 | 2023-2025 | Tremfya, Stelara, Remicade |
| Regeneron Healthcare Solutions, INC. | $160.31 | 2023-2025 | Dupixent |
| Lilly USA, LLC | $138.15 | 2024-2025 | Omvoh |
| Medtronic, INC. | $126.98 | 2022 | |
| Daiichi Sankyo INC. | $124.99 | 2021 | |
| Nestle Healthcare Nutrition INC. | $110.98 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $96.20 | 2023-2025 | Xifaxan |
| Celgene Corporation | $93.35 | 2023-2024 | Zeposia |
| Olympus America INC. | $79.11 | 2021 | |
| Pfizer INC. | $64.58 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $50.18 | 2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $49.00 | 2023 | Ocaliva |
| Celltrion USA INC. | $48.06 | 2023-2025 | Yuflyma, Vegzelma |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $37.20 | 2023 | Sutab, Suflave |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.07 | 2023 | Cyltezo |
| Qol Medical, LLC | $24.65 | 2025 | Sucraid |
| Organon LLC | $24.03 | 2024 | |
| Ironwood Pharmaceuticals, INC | $18.75 | 2024 | |
| Ferring Pharmaceuticals INC. | $17.18 | 2023 | Rebyota |
| Fresenius Kabi USA, LLC | $17.13 | 2024 | Idacio |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $16.66 | 2022 | |
| Boston Scientific Corporation | $16.49 | 2025 | Compliance Endokit |
| Gilead Sciences, INC. | $15.82 | 2023 | |
| Ardelyx, INC. | $12.77 | 2023 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Haggerty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.